A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin)

Clinical Cancer Research

Volumn 5, Issue 1, 1999, Pages 69-75

  Gerrits, Cees J H ^a   Schellens, Jan H M ^a   Burris, Howard ^b   Eckardt, John R ^b   Planting, Andre S T ^a   Van Der Burg, Maria E L ^a   Rodriguez, Gail I ^b   Loos, Walter J ^a   Van Beurden, Vera ^a   Hudson, Ian ^c   Von Hoff, Daniel D ^b   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b University of Texas Health Science Center at San Antonio   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C; NITROSOUREA DERIVATIVE; TOPOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG FORMULATION; DRUG RESISTANCE; FEMALE; GRANULOCYTOPENIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKOPENIA; MIDDLE AGED; NEOPLASMS; TOPOTECAN;

EID: 0032925377     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., and Johnson, R. K. Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34: 98-107, 1991.
2. Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Horowitz, L. A, McGuire, W. P., Sartorius, S. E., Lubejko, B. G., Kaufmann, S. H., and Donehower, R. C. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992.
3. Van Warmerdam, L. J. C., Verweij, J., Schellens, J. H. M., Rosing, H., Davies, B. E., de Boer-Dennert, M., Maes, R. A. A. A., and Beijnen, J. H. Pharmacokinetics and pharmacodynamics of topotecan administered in a daily times five regimen every three weeks. Cancer Chemother. Pharmacol., 35: 237-245, 1995.
4. Verweij, J., Lund, B., Beijnen, J. H., Rosing, H., and Hansen, H. Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol., 4: 673-678, 1993.
5. Saltz, L., Sirott, M., Young, C., Tong, W., Niedzwiecki, D., Tzy-Jyan, Y., Tao, Y., Trochowski, B, Wright, P., Barbosa, K., Toomasi, F., and Kelsen, D. Phase I clincal and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J. Natl. Cancer Inst., 85: 1499-1507, 1993.
6. Ardizonni, A., Hansen, H. H., Dombernowsky, P., Gamucci, T., Kaplan, S., Postmus, P., Giaccone, G., Schaefer, B., Wanders, J., and Verweij, J. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a Phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Developement Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol., 15: 2090-2096, 1997.
7. Creemers, G. J., Bolis, G., Gore, M., Scarfone, G., Lacave, A. J., Guastalla, J. P., Despos, R., Favelli, G., Kreinberg, R., Van Belle, S., Hudson, I., Verweij, J., and ten Bokkel Huinink, W. W. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large european Phase II study. J. Clin. Oncol., 12: 3056-3061, 1996.
8. ten Bokkel Huinink, W., Carmichael, J., Armstrong, D., Gordon, A., and Malfetano, J. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin. Oncol., 24 (Suppl. 5): S5-S19,1997.
9. ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spaczynski, M., Bolis, G., Malmstrom, H., Coleman, R., Fields, S. C., and Hern, J. F. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol., 75: 2183-2193, 1997.
10. Camilloni, G., Di Martino, E., Di Mauro, E., and Caserta, M. Regulation of the function of eukaryotic DNA topoisomerase I: topological conditions for inactivity. Proc. Natl. Acad. Sci. USA, 86: 3080-3084, 1989.
11. Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
12. Hsiang, Y. H., and Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48: 1722-1726, 1988.
13. Phillips, P. C., Janss, A., Kaufmann, S. H., Levow, C., Yao, Y., and Calvin, O. M. Topoisomerase I inhibitor schedule dependent activity and determinants of cytotoxicity in human brain tumor cell lines. Proc. Am. Assoc. Cancer Res., 35: 363, 1994.
14. Pantazis, P., Kozielski, A. J., Vardeman, D. M., Petry, E. R., and Giovanella, B. C. Efficacy of camptothecin cogeners in the treatment of human breast carcinoma xenografts. Oncol. Res., 5: 273-281, 1993.
15. Giovanella, B. C., Stehlin, J. S., Hinz, H. R., Vardeman, D., Mendoza, J. T., and Potmesil, M. Studies of time/dose intensity in treatment of human cancer xenografts with camptothecin analogues. Proc. Am. Assoc. Cancer Res., 35: 455, 1994.
16. Burris, H. A., Hanauske, A. R., Johnson, R. K., Marshall, M. H., Kuhn, J. G., Hilsenbeck, S. G., and Von Hoff, D. D. Activity of topotecan a new topoisomerase I inhibitor against human tumor colony-forming units in vitro. J. Natl. Cancer Inst., 23: 1816-1820, 1992.
17. Houghton, P. J., Cheshire, P. J., Myer, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxy-camptothecin (topotecan) against xenografts derived from adult and childhood tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1991.
18. Houghton, P. J., Chesire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitor topotecan and irinotecan administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
19. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., Vinci, R. Z., and Blum, R. H. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well tolerated regimen. J. Clin. Oncol., 12: 553-559, 1994.
20. Kuhn, J., Rizzo, J., Eckardt, J., Field, S., Cobb, P., Rodriguez, G., Rinaldi, D., Drengler, R., Smith, L., Peacock, N., Thurman, A., Delacruz, P., Hodges, S., Von Hoff, D., and Bums, H. Phase I bioavailability study of oral topotecan. Proc. Am. Soc. Clin. Oncol., 14: 474, 1995.
21. Schellens, J. H. M., Creemers, G. J., Beijnen, J. H., Rosing, H., McDonald, M., Davies, B., and Verweij, J. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br. J. Cancer, 73: 1268-1271, 1996.
22. Creemers, G. J., Gerrits, C. J. H., Schellens, J. H. M., Planting A. S., van de Burg, M. E. L., van Beurden, V. M., de Boer-Dennert, M., Harteveld, M., Loos, W., Hudson, I., Stoter, G., and Venveij, J. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J. Clin. Oncol., 149: 2540-2545, 1996.
23. Hochster, H., Speyer, J., Wadler, S., Runowicz, C., Wallach, R., Oratz, R., Chachoua, A., Sorich, J., Taubes, B., Ludwig, E., Broom, C., and Blum, R. Phase II study of topotecan 21 day infusion in platinum treated ovarian cancer: a highly active regimen. Proc. Am. Soc. Clin. Oncol., 15: 285, 1996.
24. Creemers, G. J., Gerrits, C. J. H., Eckardt, J. R., Schellens, J. H. M., Bums, H. A., Planting, A. S., Rodriguez, G. I., Loos, W. J., Hudson, I., Broom, C., Verweij, J., and Von Hoff, D. D. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J. Clin. Oncol., 75; 1087-1093, 1997.
25. National Cancer Institute, Division of Cancer Treatment. Guidelines for reporting of adverse drug reactions. Bethesda: National Cancer Institute, 1988.
26. WHO. WHO handbook for reporting results of cancer treatment. WHO offset publication No 40. Geneva, Switzerland: WHO, 1979.
27. Loos, W. J., Stoter, G., Verweij, J., and Schellens, J. H. M. Sensitive high-performance liquid Chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and the lactone ring-opened product (hydroxy-acid) in human plasma and urine. J. Chromatogr. B. Biomed. Appl., 678: 309-315, 1996.
28. Holford, N. H., and Scheiner, L. B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet., 6: 242-247, 1981.
29. Rougier, R., and Bugat, R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin. Oncol., 23: 34-41, 1996.
30. Stehlin, J. S., Natelson, E. A., Hinz, H. R., Giovanella, B. C., Ipolyi, P. D., Fehin, K. M., Trezona, T. P., Vardeman, D. M., Harris, N. J., Marcee, A. K., Kozielski, A. J., and Ruiz-Razura, A. Phase I clinical trial and pharmacokinetic results with oral administration of 20-S-camptothecin. In: M. Potmesil and H. Pinedo (eds.), Camptothecins: New Anticancer Agents, pp. 59-65. Boca Raton, FL: CRC Press, 1996.
31. Verschraegen, C. F., Natelson, E., Giovanella, B., Kavanagh, J. J., Freedman, R. S., Kudelka, A. P., Edwards, C. L., and Stehlin, J. A Phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water insoluble topoisomerase I inhibitor. Anticancer Drugs, 9: 36-44, 1998.
32. Ikuno, N., Soda, H., Wantanabe, M., and Oka, M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J. Natl. Cancer Inst., 87: 1876-1883, 1995.
33. MacDonald, J. S., Benedetti, J. K., Modiano, M., and Alberts, D. S. Phase II evaluation of topotecan in patients with advanced colorectal cancer: a Southwest Oncology Group trial. Invest. New Drugs, 75: 357-359, 1997.
34. O'Reilly, S., Donehower, R. C., Rowinsky, E. K., Ord, S., and Grochow, L. B. A Phase II trial of topotecan in patients with previously untreated pancreatic cancer. Anticancer Drugs, 7: 410-414, 1996.
35. Smith, R. E., Lew, D., Rodriguez, G. I., Taylor, S. A., Schuller, D., and Ensley, J. F. Evaluation of topotecan in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Phase II Southwest Oncology Group Study. Invest. New Drugs, 14: 403-407, 1996.
36. Kraut, E. H., Walker, M. J., Staubus, A., Gochnour, D., and Bacerrak, S. P. Phase II trial of topotecan in malignant melanoma. Cancer Invest. 15: 318-320, 1997.
37. Robert, F., Soong, S. J., and Wheeler, R. H. A Phase II study of topotecan in patients with recurrent head and neck cancer: identification of an active new agent. Am. J. Clin. Oncol., 20: 298-302, 1997.